{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:14Z","timestamp":1761870914964,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clml.2017.02.029","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T19:40:52Z","timestamp":1490902852000},"page":"375-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?"],"prefix":"10.1016","volume":"17","author":[{"given":"Govind Babu","family":"Kanakasetty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi Harsh","family":"Thanky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmaiah","family":"Kuntegowdanahalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lokanatha","family":"Dasappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh Babu","family":"Mallekavu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Lakkavalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lokesh","family":"Kadabur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudresha","family":"Antapura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.02.029_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A\u00a0new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2017.02.029_bib3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.029_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"year":"2013","series-title":"An International System for Human Cytogenetic Nomenclature","key":"10.1016\/j.clml.2017.02.029_bib6"},{"key":"10.1016\/j.clml.2017.02.029_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"year":"2008","series-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","key":"10.1016\/j.clml.2017.02.029_bib8"},{"key":"10.1016\/j.clml.2017.02.029_bib9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2017.02.029_bib10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0950-3536(98)80036-X","article-title":"The histopathology of chronic myeloproliferative diseases","volume":"11","author":"Georgii","year":"1998","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.clml.2017.02.029_bib11","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.029_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.21457","article-title":"Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia","volume":"84","author":"Foroni","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.02.029_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-76-1-95","article-title":"Unfavourable signs in patients with chronic myelocytic leukemia","volume":"76","author":"Theologides","year":"1972","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2017.02.029_bib14","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","article-title":"Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal","volume":"106","author":"Cortes","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.02.029_bib15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12185-012-1043-8","article-title":"Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study","volume":"95","author":"Trask","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2017.02.029_bib16","first-page":"3870","article-title":"Frequent deletion of hSNF5\/INI1, a component of the SWI\/SNF complex, in chronic myeloid leukemia","volume":"59","author":"Grand","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.02.029_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cancergencyto.2006.10.006","article-title":"On the genesis and prognosis of variant translocations in chronic myeloid leukemia","volume":"173","author":"Gorusu","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.clml.2017.02.029_bib18","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Quintas-Cardama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib19","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib20","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood.V118.21.782.782","article-title":"Impact of additional cytogenetic alterations at diagnosis on prognosis of CML: long-term observation from 1151 patients of the randomized CML Study IV abstract. ASH Annual Meeting Abstracts","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.029_bib23","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.029_bib24","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib25","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.029_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2141.1981.tb02765.x","article-title":"Staging of chronic myeloid leukaemia","volume":"47","author":"Tura","year":"1981","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.029_bib27","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2011.37.6962","article-title":"European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation","volume":"29","author":"Marin","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.029_bib28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.02.029_bib29","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib31","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V60.6.1298.1298","article-title":"A\u00a0multivariate analysis of prognostic factors in chronic myeloid leukemia","volume":"60","author":"Cervantes","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.exphem.2003.08.006","article-title":"Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate","volume":"31","author":"Tipping","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2017.02.029_bib33","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1158\/1078-0432.CCR-0785-3","article-title":"Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571)","volume":"10","author":"Dressman","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.02.029_bib34","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.02.029_bib35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cncr.20457","article-title":"Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in\u00a0vitro incubation","volume":"101","author":"Cilloni","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.02.029_bib36","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1182\/blood-2005-01-0210","article-title":"Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment","volume":"105","author":"Schultheis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib37","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1182\/blood.V118.21.2503.2503","volume":"118","author":"Quintas-Cardama","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib38","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In\u00a0vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML","volume":"106","author":"White","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.029_bib39","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.029_bib40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hon.2005","article-title":"Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC","volume":"30","author":"Koren-Michowitz","year":"2012","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2017.02.029_bib41","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanism of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J\u00a0Clin Invest"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501630725X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501630725X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:35Z","timestamp":1761870515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501630725X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S215226501630725X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.029","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}